


Consolidated controlling net income came to **COP 4.9 trillion**, thereby reflecting our strategy as an investment manager

This bottom line reflects our strategy as well as the organic growth seen with the recurring revenues in local currency obtained from our subsidiaries.

RELEVANT FIGURES FOR Q1 2024

Stated in COP billions

CONTROLLING NET INCOME




Please bear in mind:

In order to make comparable the consolidated results versus the first quarter of 2023, the non-recurring effects recognized during the quarter include:

- The gain on the sale of Nutresa amounting to COP 4 trillion along with COP 362 billion in taxes associated with this transaction.
- A gain from the Grupo Argos transactions as recorded via the equity method of COP 623 billion, this being mainly the Argos USA transaction.
- Lower revenues via the equity method mainly due to the fact that Nutresa is no longer being accounted for, this compared to the same quarter last year.
- The effect of the appreciation of the Colombian peso against other Latin American currencies.

OPERATING REVENUES


Recurrent Variation: -1%



Recurrent Revenues + 7% in local currency
Reflecting growth in premiums and fee and commission income

OPERATING EARNINGS

Recurrent Variation: -1%



Recurrent Operating Earnings + 7% in local currency

* ROE and ROTE adjusted for: 1) Amortization of intangible assets resulting from acquisitions is added to net income, 2) Valuations of associates and cross-shareholdings between Grupo Argos and Grupo SURA are excluded from the Shareholders' Equity account, 3) Non-recurring impacts associated with the Nutresa transaction in 2023 and 2024 and the impact of the divestitures in Argentina and El Salvador are returned to net income. 4). As of the third quarter of 2023, the Nutresa investment is excluded from the Equity account since it is no longer being recognized via revenues obtained via the equity method.

Grupo SURA's results for this first quarter were driven by an increase in revenues from SURA Asset Management and Suramericana, as well as by the gain recorded on the share swap regarding the Nutresa transaction now that the Framework Agreement has been successfully completed. This allowed us to reflect the growth of said Company for a span of more than 40 years in which it formed part of our investment portfolio.


The recurring figures are the result of the positive dynamics of our different lines of business, which reaffirms the strength of a powerful portfolio with a greater focus on the financial

Ricardo Jaramillo Mejía,
CEO of Grupo SURA



PROGRESS MADE IN TERMS OF
DIVIDEND DIVERSIFICATION BY COUNTRY

Distribution by country of total estimated dividends for 2024



Grupo SURA expects to receive dividends from its portfolio companies worth approximately

COP 2 trillion

Nearly half of this figure comes from operations outside Colombia.

THE FRAMEWORK AGREEMENT NOW COMPLETED

The Nutresa transaction, including the tender offer and the second share swap were successfully completed. This Framework Agreement was signed on June 15, 2023.

This has led to a change in the Company's ownership structure, a greater focus on financial services on the part of our portfolio along with an increase in the stakes held by all our shareholders thanks to the repurchase of 31.8% of the Company's outstanding ordinary shares, once the Sociedad Portfolio is duly wound up.

FINANCIAL RESULTS ON AN INDIVIDUAL SUBSIDIARY LEVEL

Suramericana

(Seguros, Tendencias y Riesgos)

Written premiums

COP 6.9 trillion

▲ 11%

at constant exchange rates

Breakdown of written premiums by segment



Net income

COP 257 billion

▼ 19%

1Q23 vs. 1Q24 with recurring effects

SURA Asset Management

(Pensiones, Ahorro, Gestión de Activos)

Fee and commission income

COP 947* billion

▲ 10%

AUM

COP 691* trillion

▲ 15%

Controlling net income

COP 318* billion

▲ 54%

*Excluding exchange rate effects

HIGHLIGHTS

S&P Ratified its Credit Rating

On March 27, 2024, S&P Global affirmed the Company's "BB+" rating, with a negative outlook. The firm recognizes our ability to meet our debt commitments thanks to our positive levels of liquidity.

Approval of an all-time high dividend

Grupo SURA's General Assembly of Shareholders declared a dividend payment of COP 1,400 per share for 2024, that is to say 9.4% higher than for last year and the highest in its history.

COP 1,400 per share of 2024

▲ 9.4%

Merco ESG Colombia

SURA was ranked in top position from the insurance sector and sixth overall in the 2024 MERCO ESG Responsibility ranking. Consequently, we have been among the 10 best-performing organizations in this area in Colombia for the last 9 consecutive years.

1st top position from the insurance

6th in the 2024 MERCO ESG Responsibility ranking.

VaxThera inaugurates its vaccine manufacturing plant

This SURA biotechnology company has now started operating the first stage of its new vaccine packaging and finishing plant in Rionegro (Antioquia).

Suramericana, through its subsidiary in Colombia, has invested USD 100 million since 2021 in VaxThera.

Suramericana, has invested in Vaxthera

USD 100 million since 2021

Our growth is based on a long-term view while reflecting the strength of our investments